These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 36446898)

  • 1. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice.
    Lim LL; Chow E; Chan JCN
    Nat Rev Endocrinol; 2023 Mar; 19(3):151-163. PubMed ID: 36446898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus.
    Kim CH; Hwang IC; Choi HM; Ahn CH; Yoon YE; Cho GY
    Int J Cardiol; 2022 Oct; 364():104-111. PubMed ID: 35716949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
    Sim R; Chong CW; Loganadan NK; Fong AYY; Navaravong L; Hussein Z; Khunti K; Lee SWH
    Diabet Med; 2022 Mar; 39(3):e14780. PubMed ID: 34962662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.
    Fadini GP; Frison V; Simioni N; Lapolla A; Gatti A; Bossi AC; Del Buono A; Fornengo P; Gottardo L; Laudato M; Perseghin G; Bonora E; Avogaro A
    J Am Heart Assoc; 2019 Jul; 8(14):e012244. PubMed ID: 31269877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry.
    García-Vega D; Cinza-Sanjurjo S; Eiras S; González-Juanatey JR
    Am J Med; 2024 Aug; 137(8):761-769.e1. PubMed ID: 38729592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrovascular Complications.
    McRae M; Low Wang CC
    Prim Care; 2022 Jun; 49(2):255-273. PubMed ID: 35595481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes.
    Limonte CP; Hall YN; Trikudanathan S; Tuttle KR; Hirsch IB; de Boer IH; Zelnick LR
    J Diabetes Complications; 2022 Jun; 36(6):108204. PubMed ID: 35537891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study.
    Hao R; Myroniuk T; McGuckin T; Manca D; Campbell-Scherer D; Lau D; Yeung RO
    BMC Prim Care; 2022 May; 23(1):124. PubMed ID: 35606699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
    Khan MS; Fonarow GC; McGuire DK; Hernandez AF; Vaduganathan M; Rosenstock J; Handelsman Y; Verma S; Anker SD; McMurray JJV; Kosiborod MN; Butler J
    Circulation; 2020 Sep; 142(12):1205-1218. PubMed ID: 32955939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
    Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Antidiabetes Medications and Their Cardiovascular and Renal Benefits.
    Ferro EG; Elshazly MB; Bhatt DL
    Cardiol Clin; 2021 Aug; 39(3):335-351. PubMed ID: 34247748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
    Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM
    Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes.
    Marasinghe DH; Butalia S; Garies S; Drummond N; Kim JW; Senior PA
    Can J Diabetes; 2022 Jul; 46(5):487-494. PubMed ID: 35739042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials: Implications for practice.
    Battise DM; Olin JL
    J Am Assoc Nurse Pract; 2021 Mar; 33(12):1139-1147. PubMed ID: 33105320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.
    Cherney DZI; Udell JA; Drucker DJ
    Med; 2021 Nov; 2(11):1203-1230. PubMed ID: 35590197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.
    Akiyama H; Nishimura A; Morita N; Yajima T
    Front Endocrinol (Lausanne); 2023; 14():1111984. PubMed ID: 36793276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.